Study of DM5167 in Patients With Advanced Solid Tumors
Recruiting
Phase 1
Interventional Study
Advanced Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 58 (estimated)
- Sponsor
- DIGMBIO · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Men and women aged 19 years or older as of the date of written informed consent
* Patients who have at least one measurable lesion according to RECIST version 1.1
* ECOG performance status ≤ 1
* Patients with life expectancy ≥ 12 weeks
* Patients who meet the clinical laborato…
Contacts